the aid library

LIST OPTIONS

Filter

869

WHO European framework for action on mental health 2021-2025: draft for the Seventy-first Regional Committee for Europe

World Health Organization WHO (2021) C_WHO

The framework sets out a response to current mental health challenges arising from the negative impact that the COVID-19 pandemic has had on population mental health and well-being. The EFAMH provides a coherent basis for intensified efforts to mainstream, promote and safeguard mental well-being as ... more

Download (1421)

View PDF (1294)

Prevention of Mother-to-Child Transmission of HIV Generic Training Package - Trainer Manual

WHO, HHS-CDC, GAP WHO, HHS-CDC (2008)

Download (295)

View PDF (313)

Arrangements for Public Communication in Preparedness and Response for a Nuclear or Radiological Emergency

International Atomic Energy Agency IAEA, WHO; OCHA; ET al. (2020) C_WHO

IAEA Safety Standards for protecting people and the environment

Download (153)

View PDF (171)

Community Engagement During COVID-19: A Guide for Community-Facing Staff

Oxfam (2020) C2

This guide is intended to support teams working directly with communities during the Covid-19 pandemic. It provides general guidance on community engagement during outbreak responses, including how to support an integrated response, as well as outbreak prevention and response.

Download (304)

View PDF (167)

Analysis of Pandemic Preparedness and Response (PPR) architecture, financing needs, gaps and mechanisms

World Bank (2022) CC

A global Pandemic, Preparedness and Response (RRR) architecture

Download (424)

View PDF (563)

Contextual Factors Influencing Modern Contraceptive Use in Nigeria

Ejembi, Clara Ladi, Tukur Dahiru, and Alhaji A. Aliyu ICF International (2015) C2

DHS Working Papers No. 120

Download (132)

View PDF (155)

Strategies and interventions on preventing and responding to violence and injuries among refugees and migrants (2020)

World Health Organization WHO (2020) C_WHO

This technical guidance outlines current evidence, knowledge and best practice relating to incidences of violence and injuries among refugees and migrants in the WHO European Region. It highlights key principles, summarizes priority actions and challenges, maps existing international commitments and... more

Download (211)

View PDF (209)

O papel dos agentes comunitários de saúde na vacinação contra a COVID-19: guia de apoio à implementaçao

Organização Mundial da Saúde (OMS); UNICEF (2021) C_WHO

The role of community health workers in the vaccination against COVID-19: guide to support the implementation of the vaccination programme

Download (273)

View PDF (261)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (223)

View PDF (249)

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

Download (197)

View PDF (200)

COVID-19: Guidelines for communicating about coronavirus disease 2019 - A guide for leaders

Pan American Health Organisation PAHO (2020) C_WHO

Risk communication encompasses all the basics of health communication but differs in the need for speed and reliance on trust. At times of crisis, leaders are called on to provide a quick, sensitive and trustworthy response.

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (572)

View PDF (1181)

International technical guidance on sexuality education. An evidence-informed approach.

UNESCO (2018) CC

This revised and fully updated edition of the International technical guidance on sexuality education benefits from a new review of the current evidence, and reaffirms the position of sexuality education within a framework of human rights and gender equality. It promotes structured learning about... more

Download (158)

View PDF (170)

Save the Children's COVID-19 Program Framework and Guidance and Companion Pieces

Save the Children (2020) C1

How we respond both now and going forward will help mitigate the impact of COVID-19, and to the extent possible preserve children’s rights to Survive, Learn, and Be Protected. We will focus our efforts on the most critical work essential to maintaining these commitments to the extent possible.

Download (226)

View PDF (302)

Taking a Multisectoral, One Health Approach:A Tripartite Guide to Addressing Zoonotic Diseases in Countries

FAO, OIE, WHO (2019) C_WHO

A multidisciplinary and multisectoral collaboration, through a One Health approach is required to effectively prepare for, detect, assess, and respond to emerging and endemic zoonotic diseases. However, external and internal health system evaluations continue to identify major gaps in capacity ... more

Download (163)

View PDF (188)

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that policies can be tailored to different population groups. ... more

Download (188)

View PDF (255)

The ACT-Accelerator: Two years of impact

World Health Organization WHO (2022) C_WHO

The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.

Download (629)

View PDF (550)

Infant and young child feeding counselling: an integrated course: participant's manual
recommended

World Health Organization WHO; UNICEF (2021) C_WHO

The Participant’s manual contains summaries of information presented by the trainers, copies of worksheets and checklists for the clinical practice and practical sessions, and exercises that participants will do during the course. One manual should be provided for each participant, using the modul... more

Download (225)

View PDF (258)

Centering communities in pandemic preparedness and response

The Independent Panel (2021) CC

Background paper 10 The Independent Panel for Pandemic Preparedness and Response May 2021

Infant and young child feeding counselling: an integrated course: participant's manual recommended

Infant and young child feeding counselling: an integrated course: participant's manual
recommended